• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

浸润性肝细胞癌:见林而非树。

Infiltrating hepatocellular carcinoma: seeing the tree through the forest.

机构信息

Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

出版信息

J Gastrointest Surg. 2011 Nov;15(11):2089-97. doi: 10.1007/s11605-011-1614-7. Epub 2011 Jul 2.

DOI:10.1007/s11605-011-1614-7
PMID:21725699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3580771/
Abstract

INTRODUCTION

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection.

DISCUSSION

Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly.

CONCLUSION

Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.

摘要

介绍

肝细胞癌(HCC)是全球癌症相关死亡的主要原因。传统上,这种疾病很难治愈,尤其是在晚期发现时,因此早期诊断和干预至关重要。HCC 通常在慢性肝病的背景下发生,其形态表现多样。其中最难在早期监测影像中识别的是浸润性亚型,它可能占所有 HCC 病例的 13%,并且可能与乙型肝炎感染的背景更为密切相关。

讨论

某些影像学特征可以提供重要线索,包括磁共振成像(MRI)T1 和 T2 序列上的信号强度差异,以及门静脉血栓的存在/表现。由于肿瘤具有弥漫性和浸润性,手术切除和移植很少是可行的治疗选择。其他形式的肝定向治疗也有尝试,但效果有限,发病率高。迄今为止,尚无数据可确定不同 HCC 亚型对系统治疗的反应是否不同,因此这可能是最合理的方法。未接受治疗的患者通常会很快进展为肝衰竭。

结论

浸润性 HCC 可能非常微妙,因此很难检测到,尤其是在肝硬化的背景下。照顾肝炎、慢性肝病和肝硬化患者的医务人员必须在评估监测影像时保持高度警惕,以便尽早发现这种 HCC 亚型,并启动多学科治疗计划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/32aba08e3f5d/nihms438310f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/0d8165a0e47a/nihms438310f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/b8449768a084/nihms438310f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/3282637b051b/nihms438310f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/de52ada907e7/nihms438310f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/32aba08e3f5d/nihms438310f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/0d8165a0e47a/nihms438310f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/b8449768a084/nihms438310f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/3282637b051b/nihms438310f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/de52ada907e7/nihms438310f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bac5/3580771/32aba08e3f5d/nihms438310f5.jpg

相似文献

1
Infiltrating hepatocellular carcinoma: seeing the tree through the forest.浸润性肝细胞癌:见林而非树。
J Gastrointest Surg. 2011 Nov;15(11):2089-97. doi: 10.1007/s11605-011-1614-7. Epub 2011 Jul 2.
2
Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis.肝癌监测和适当的治疗选择可改善肝硬化患者的生存。
Eur J Cancer. 2010 Mar;46(4):744-51. doi: 10.1016/j.ejca.2009.12.018. Epub 2010 Jan 8.
3
Hepatocellular carcinoma and other liver lesions.肝细胞癌及其他肝脏病变。
Med Clin North Am. 2014 Jan;98(1):103-18. doi: 10.1016/j.mcna.2013.09.003. Epub 2013 Oct 18.
4
Viral hepatitis and hepatocellular carcinoma.病毒性肝炎与肝细胞癌
Arch Med Res. 2007 Aug;38(6):612-20. doi: 10.1016/j.arcmed.2006.09.004.
5
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.从肝癌的诊断到治疗:发达国家和发展中国家共同面临的流行问题。
World J Gastroenterol. 2017 Aug 7;23(29):5282-5294. doi: 10.3748/wjg.v23.i29.5282.
6
[Small hepatocellular carcinoma in patients with hepatitis B-induced cirrhosis: a comparison between MRI and MDCT].[乙型肝炎所致肝硬化患者的小肝细胞癌:MRI与MDCT的比较]
Beijing Da Xue Xue Bao Yi Xue Ban. 2010 Dec 18;42(6):767-72.
7
Advances in Management of Hepatocellular Carcinoma.肝细胞癌管理的进展
Asian Pac J Cancer Prev. 2016;17(8):3697-703.
8
Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer.miRNAs 在肝癌诊断和预后标志物中的潜在应用。
Front Biosci (Landmark Ed). 2013 Jan 1;18(1):199-223. doi: 10.2741/4096.
9
HBV-related HCC, clinical issues and therapy.HBV 相关 HCC,临床问题与治疗。
Dig Liver Dis. 2011 Jan;43 Suppl 1:S32-9. doi: 10.1016/S1590-8658(10)60690-1.
10
Diffuse infiltrative hepatocellular carcinoma: Multimodality imaging manifestations.弥漫浸润型肝细胞癌:多模态影像学表现
J Surg Oncol. 2023 Mar;127(3):385-393. doi: 10.1002/jso.27138. Epub 2022 Nov 14.

引用本文的文献

1
Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.浸润性肝细胞癌全身治疗的疗效
J Hepatocell Carcinoma. 2025 Jun 23;12:1221-1229. doi: 10.2147/JHC.S528897. eCollection 2025.
2
Managing Complex Hepatocellular Carcinoma Subtypes: Diffuse Infiltrative, Large Tumours, and Tumour Rupture-The Challenges and Strategies.复杂肝细胞癌亚型的管理:弥漫浸润型、大肿瘤及肿瘤破裂——挑战与策略
J Clin Exp Hepatol. 2025 May-Jun;15(3):102505. doi: 10.1016/j.jceh.2025.102505. Epub 2025 Jan 22.
3
Comparing immunotherapy effectiveness for unresectable hepatocellular carcinoma: infiltrative versus non-infiltrative types in real-world settings.

本文引用的文献

1
A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.一项比较符合米兰标准的 HCC 的射频消融与手术切除的随机临床试验。
Ann Surg. 2010 Dec;252(6):903-12. doi: 10.1097/SLA.0b013e3181efc656.
2
Loco-regional treatment of hepatocellular carcinoma.局部区域治疗肝细胞癌。
Hepatology. 2010 Aug;52(2):762-73. doi: 10.1002/hep.23725.
3
Serum markers of hepatocellular carcinoma.肝细胞癌的血清标志物。
比较不可切除肝细胞癌免疫治疗的有效性:真实世界中浸润型与非浸润型的对比
Ther Adv Med Oncol. 2025 Jan 7;17:17588359241312141. doi: 10.1177/17588359241312141. eCollection 2025.
4
Multiphasic Computed Tomography Enhancement Characteristics and Utility of Delayed Phase in Infiltrative Hepatocellular Carcinoma.多期计算机断层扫描增强特征及延迟期在浸润性肝细胞癌中的应用价值
Indian J Radiol Imaging. 2024 Aug 14;35(1):67-72. doi: 10.1055/s-0044-1789191. eCollection 2025 Jan.
5
Optimizing US for HCC surveillance.优化超声用于肝细胞癌监测
Abdom Radiol (NY). 2025 Jun;50(6):2453-2463. doi: 10.1007/s00261-024-04631-y. Epub 2024 Nov 25.
6
Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.肝动脉灌注化疗联合乐伐替尼和PD - 1抑制剂可改善浸润性肝细胞癌的生存率:一项多中心队列研究
J Hepatocell Carcinoma. 2024 Sep 9;11:1727-1740. doi: 10.2147/JHC.S477872. eCollection 2024.
7
A rare and challenging case of extrahepatic costal metastases from an unknown primary hepatocellular carcinoma.一例罕见且具有挑战性的原发性不明肝细胞癌肝外肋骨转移病例。
Gastroenterol Hepatol Bed Bench. 2024;17(1):93-99. doi: 10.22037/ghfbb.v17i1.2812.
8
Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics.用于解剖分割、肝脏容积测量和影像组学提取的自动化磁共振成像肝脏分割
Eur Radiol. 2024 Aug;34(8):5056-5065. doi: 10.1007/s00330-023-10495-5. Epub 2024 Jan 13.
9
Radiomics-Based Prediction of Future Portal Vein Tumor Infiltration in Patients with HCC-A Proof-of-Concept Study.基于影像组学预测肝癌患者未来门静脉肿瘤浸润——一项概念验证研究
Cancers (Basel). 2022 Dec 8;14(24):6036. doi: 10.3390/cancers14246036.
10
Imaging Spectrum of Intrahepatic Mass-Forming Cholangiocarcinoma and Its Mimickers: How to Differentiate Them Using MRI.肝内肿块型胆管细胞癌及其模拟病变的影像学表现:MRI 如何对其进行鉴别。
Curr Oncol. 2022 Jan 30;29(2):698-723. doi: 10.3390/curroncol29020061.
Dig Dis Sci. 2010 Oct;55(10):2744-55. doi: 10.1007/s10620-010-1184-7. Epub 2010 Mar 26.
4
The radiological diagnosis of hepatocellular carcinoma.肝细胞癌的放射学诊断。
Am J Gastroenterol. 2010 Mar;105(3):610-2. doi: 10.1038/ajg.2009.663.
5
Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging.肝细胞癌患者门静脉良、恶性血栓的鉴别诊断:弥散加权 MR 成像的应用。
Radiology. 2010 Jan;254(1):154-62. doi: 10.1148/radiol.09090304.
6
Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis.代偿良好的肝硬化患者早期肝细胞癌的管理
Ann Surg Oncol. 2009 Jul;16(7):1820-31. doi: 10.1245/s10434-009-0364-1. Epub 2009 Mar 7.
7
Hepatitis B virus induced hepatocellular carcinoma.乙型肝炎病毒诱发的肝细胞癌。
Cancer Lett. 2009 Dec 1;286(1):52-9. doi: 10.1016/j.canlet.2008.12.003. Epub 2009 Jan 14.
8
Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation--eighteen months of follow-up: a case report.肝移植后诊断的类肝硬化型肝细胞癌——18个月随访:病例报告
Transplant Proc. 2008 Oct;40(8):2835-6. doi: 10.1016/j.transproceed.2008.07.012.
9
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
10
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies.肝硬化肝脏中肝细胞癌的磁共振成像:挑战与争议
Radiology. 2008 May;247(2):311-30. doi: 10.1148/radiol.2472061331.